Chapter 13: Current findings from prophylactic HPV vaccine trials (Q36584357)

15 August 2017

1 reference

title

Chapter 13: Current findings from prophylactic HPV vaccine trials (English)

1 reference

15 August 2017

1 reference

1 reference

1

Laura A Koutsky

1 reference

15 August 2017

Diane M Harper

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

23 June 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

24 Suppl 3

1 reference

15 August 2017

page(s)

S3/114-21

1 reference

Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

Epidemiologic classification of human papillomavirus types associated with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

Detection with the polymerase chain reaction of human papillomavirus DNA in condylomata acuminata treated with CO2 laser and microwave

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

Randomized clinical trial of PCR-determined human papillomavirus detection methods: self-sampling versus clinician-directed--biologic concordance and women's preferences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

Natural history of dysplasia of the uterine cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

Consistency in the histological diagnosis of epithelial abnormalities of the cervix uteri

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

Interobserver variation in histopathological grading of cervical dysplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

Observer variation in histopathological diagnosis and grading of cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.014

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2006.06.014

1 reference

15 August 2017

1 reference